Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Pharmacokinetic and Drug-Drug Interaction Profiles of the Combination of Tezacaftor/Ivacaftor.

Garg V, Shen J, Li C, Agarwal S, Gebre A, Robertson S, Huang J, Han L, Jiang L, Stephan K, Wang LT, Lekstrom-Himes J.

Clin Transl Sci. 2019 May;12(3):267-275. doi: 10.1111/cts.12610. Epub 2019 Jan 29.

2.

Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del.

Taylor-Cousar JL, Munck A, McKone EF, van der Ent CK, Moeller A, Simard C, Wang LT, Ingenito EP, McKee C, Lu Y, Lekstrom-Himes J, Elborn JS.

N Engl J Med. 2017 Nov 23;377(21):2013-2023. doi: 10.1056/NEJMoa1709846. Epub 2017 Nov 3.

3.

Tezacaftor-Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis.

Rowe SM, Daines C, Ringshausen FC, Kerem E, Wilson J, Tullis E, Nair N, Simard C, Han L, Ingenito EP, McKee C, Lekstrom-Himes J, Davies JC.

N Engl J Med. 2017 Nov 23;377(21):2024-2035. doi: 10.1056/NEJMoa1709847. Epub 2017 Nov 3.

4.

Tezacaftor/Ivacaftor in Subjects with Cystic Fibrosis and F508del/F508del-CFTR or F508del/G551D-CFTR.

Donaldson SH, Pilewski JM, Griese M, Cooke J, Viswanathan L, Tullis E, Davies JC, Lekstrom-Himes JA, Wang LT; VX11-661-101 Study Group.

Am J Respir Crit Care Med. 2018 Jan 15;197(2):214-224. doi: 10.1164/rccm.201704-0717OC.

5.

Continuous intravesical lidocaine treatment for interstitial cystitis/bladder pain syndrome: safety and efficacy of a new drug delivery device.

Nickel JC, Jain P, Shore N, Anderson J, Giesing D, Lee H, Kim G, Daniel K, White S, Larrivee-Elkins C, Lekstrom-Himes J, Cima M.

Sci Transl Med. 2012 Jul 18;4(143):143ra100. doi: 10.1126/scitranslmed.3003804.

6.

Effect of CC chemokine receptor 2 CCR2 blockade on serum C-reactive protein in individuals at atherosclerotic risk and with a single nucleotide polymorphism of the monocyte chemoattractant protein-1 promoter region.

Gilbert J, Lekstrom-Himes J, Donaldson D, Lee Y, Hu M, Xu J, Wyant T, Davidson M; MLN1202 Study Group.

Am J Cardiol. 2011 Mar 15;107(6):906-11. doi: 10.1016/j.amjcard.2010.11.005. Epub 2011 Jan 19.

PMID:
21247529
7.

Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus.

McHutchison JG, Bacon BR, Gordon SC, Lawitz E, Shiffman M, Afdhal NH, Jacobson IM, Muir A, Al-Adhami M, Morris ML, Lekstrom-Himes JA, Efler SM, Davis HL.

Hepatology. 2007 Nov;46(5):1341-9.

PMID:
17929306
8.

Safety, pharmacokinetics and immune effects in normal volunteers of CPG 10101 (ACTILON), an investigational synthetic toll-like receptor 9 agonist.

Vicari AP, Schmalbach T, Lekstrom-Himes J, Morris ML, Al-Adhami MJ, Laframboise C, Leese P, Krieg AM, Efler SM, Davis HL.

Antivir Ther. 2007;12(5):741-51.

PMID:
17713157
9.

Metabolic response of mice to a postnatal ablation of CCAAT/enhancer-binding protein alpha.

Yang J, Croniger CM, Lekstrom-Himes J, Zhang P, Fenyus M, Tenen DG, Darlington GJ, Hanson RW.

J Biol Chem. 2005 Nov 18;280(46):38689-99. Epub 2005 Sep 15.

10.

Human platelets exhibit chemotaxis using functional N-formyl peptide receptors.

Czapiga M, Gao JL, Kirk A, Lekstrom-Himes J.

Exp Hematol. 2005 Jan;33(1):73-84.

PMID:
15661400
11.

Human neutrophil collagenase expression is C/EBP-dependent during myeloid development.

Khanna-Gupta A, Zibello T, Idone V, Sun H, Lekstrom-Himes J, Berliner N.

Exp Hematol. 2005 Jan;33(1):42-52.

PMID:
15661397
12.

Inhibition of human neutrophil IL-8 production by hydrogen peroxide and dysregulation in chronic granulomatous disease.

Lekstrom-Himes JA, Kuhns DB, Alvord WG, Gallin JI.

J Immunol. 2005 Jan 1;174(1):411-7.

13.

Enhancement of hematopoietic stem cell repopulating capacity and self-renewal in the absence of the transcription factor C/EBP alpha.

Zhang P, Iwasaki-Arai J, Iwasaki H, Fenyus ML, Dayaram T, Owens BM, Shigematsu H, Levantini E, Huettner CS, Lekstrom-Himes JA, Akashi K, Tenen DG.

Immunity. 2004 Dec;21(6):853-63.

14.
15.

Novel combinatorial interactions of GATA-1, PU.1, and C/EBPepsilon isoforms regulate transcription of the gene encoding eosinophil granule major basic protein.

Du J, Stankiewicz MJ, Liu Y, Xi Q, Schmitz JE, Lekstrom-Himes JA, Ackerman SJ.

J Biol Chem. 2002 Nov 8;277(45):43481-94. Epub 2002 Aug 28.

16.

C/EBPalpha is required for proteolytic cleavage of cyclin A by calpain 3 in myeloid precursor cells.

Welm AL, Timchenko NA, Ono Y, Sorimachi H, Radomska HS, Tenen DG, Lekstrom-Himes J, Darlington GJ.

J Biol Chem. 2002 Sep 13;277(37):33848-56. Epub 2002 Jul 8.

17.

Inherited Neutrophil Disorders: Molecular Basis and New Therapies.

Dinauer MC, Lekstrom-Himes JA, Dale DC.

Hematology Am Soc Hematol Educ Program. 2000:303-318.

PMID:
11701548
18.

C/EBP epsilon mediates myeloid differentiation and is regulated by the CCAAT displacement protein (CDP/cut).

Khanna-Gupta A, Zibello T, Sun H, Lekstrom-Himes J, Berliner N.

Proc Natl Acad Sci U S A. 2001 Jul 3;98(14):8000-5.

19.

C/EBPepsilon -/- mice: increased rate of myeloid proliferation and apoptosis.

Verbeek W, W├Ąchter M, Lekstrom-Himes J, Koeffler HP.

Leukemia. 2001 Jan;15(1):103-11.

20.
22.

Immunodeficiency diseases caused by defects in phagocytes.

Lekstrom-Himes JA, Gallin JI.

N Engl J Med. 2000 Dec 7;343(23):1703-14. Review. No abstract available.

PMID:
11106721
23.
24.

Myeloid transcription factor C/EBPepsilon is involved in the positive regulation of lactoferrin gene expression in neutrophils.

Verbeek W, Lekstrom-Himes J, Park DJ, Dang PM, Vuong PT, Kawano S, Babior BM, Xanthopoulos K, Koeffler HP.

Blood. 1999 Nov 1;94(9):3141-50.

PMID:
10556201
25.
26.
27.

Association of major histocompatibility complex determinants with the development of symptomatic and asymptomatic genital herpes simplex virus type 2 infections.

Lekstrom-Himes JA, Hohman P, Warren T, Wald A, Nam JM, Simonis T, Corey L, Straus SE.

J Infect Dis. 1999 May;179(5):1077-85.

PMID:
10191207
28.

CCAAT/enhancer binding proteins are critical components of the transcriptional regulation of hematopoiesis (Review).

Yamanaka R, Lekstrom-Himes J, Barlow C, Wynshaw-Boris A, Xanthopoulos KG.

Int J Mol Med. 1998 Jan;1(1):213-21. Review.

PMID:
9852222
29.

Biological role of the CCAAT/enhancer-binding protein family of transcription factors.

Lekstrom-Himes J, Xanthopoulos KG.

J Biol Chem. 1998 Oct 30;273(44):28545-8. Review.

30.
32.

Impaired granulopoiesis, myelodysplasia, and early lethality in CCAAT/enhancer binding protein epsilon-deficient mice.

Yamanaka R, Barlow C, Lekstrom-Himes J, Castilla LH, Liu PP, Eckhaus M, Decker T, Wynshaw-Boris A, Xanthopoulos KG.

Proc Natl Acad Sci U S A. 1997 Nov 25;94(24):13187-92.

33.

Targeted expression of Cre recombinase to adipose tissue of transgenic mice directs adipose-specific excision of loxP-flanked gene segments.

Barlow C, Schroeder M, Lekstrom-Himes J, Kylefjord H, Deng CX, Wynshaw-Boris A, Spiegelman BM, Xanthopoulos KG.

Nucleic Acids Res. 1997 Jun 15;25(12):2543-5. Erratum in: Nucleic Acids Res 1997 Nov 1;25(21):4429.

34.

CCAAT/enhancer binding protein epsilon is preferentially up-regulated during granulocytic differentiation and its functional versatility is determined by alternative use of promoters and differential splicing.

Yamanaka R, Kim GD, Radomska HS, Lekstrom-Himes J, Smith LT, Antonson P, Tenen DG, Xanthopoulos KG.

Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):6462-7.

35.

Periodic illness associated with Epstein-Barr virus infection.

Lekstrom-Himes JA, Dale JK, Kingma DW, Diaz PS, Jaffe ES, Straus SE.

Clin Infect Dis. 1996 Jan;22(1):22-7.

PMID:
8824960
36.

Treatment with intralesional granulocyte instillations and interferon-gamma for a patient with chronic granulomatous disease and multiple hepatic abscesses.

Lekstrom-Himes JA, Holland SM, DeCarlo ES, Miller J, Leitman SF, Chang R, Baker AR, Gallin JI.

Clin Infect Dis. 1994 Oct;19(4):770-3.

PMID:
7803648

Supplemental Content

Loading ...
Support Center